Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 33Leukemia, Myeloid, Acute 24Melanoma 14Colorectal Neoplasms 14Breast Neoplasms 14Multiple Myeloma 13Myelodysplastic Syndromes 12Leukemia, Lymphocytic, Chronic, B-Cell 12Pancreatic Neoplasms 10Lymphoma, Follicular 10Prostatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Large B-Cell, Diffuse 8Triple Negative Breast Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Lung Neoplasms 7Burkitt Lymphoma 7Ovarian Neoplasms 6Lymphoma, B-Cell, Marginal Zone 6Stomach Neoplasms 5Sarcoma 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, T-Cell 5Lymphoma, B-Cell 5Lymphoma 5Leukemia, Biphenotypic, Acute 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Unspecified Adult Solid Tumor, Protocol Specific 4

Interventions

Oxaliplatin 5S 1 (combination) 4Irinotecan 4pembrolizumab 3IFL protocol 3Fluorouracil 3Bevacizumab 3amminedichloro(2-methylpyridine)platinum(II) 2N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2MLN 8237 2Leucovorin 2Gemcitabine 2Folfox protocol 2Fecal Microbiota Transplantation 2Drug Therapy 2Doxorubicin 2Cyclophosphamide 2Cisplatin 2Cetuximab 2Capecitabine 2CGX1321 2ulixertinib 1tivozanib 1titanium silicide 1tislelizumab 1sodium thiosulfate 1sacituzumab govitecan 1remune 1plecanatide 1phosphatidyltransferase, Clostridium butyricum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gastrointestinal Neoplasms × Biopsy × Clear all
NCT05107219 2026-04-07

GCC Agonist Signal in the Small Intestine

University of Wisconsin, Madison

Phase 1 Completed
43 enrolled
Gastrointestinal

Barrett Esophagus, Gastroesophageal Reflux, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡